|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, Vol. 91 No. 1 (January 1), 1998:
pp. 89-99
By
From the Departments of Laboratory Medicine and Medicine, University
of California School of Medicine and the Veterans Affairs Medical
Center, San Francisco, CA.
Administration of macrophage colony-stimulating factor (M-CSF) to
mice (2 to 8 mg/kg/d × 5d) produced dose-dependent thrombocytopenia,
which reached its nadir on days 4 to 5, followed by rapid recovery.
Surprisingly, when administration of M-CSF was prolonged, the
thrombocytopenia completely resolved, despite continued treatment.
Splenectomy did not prevent the thrombocytopenia. Readministration of
M-CSF after various intervals continued to produce the thrombocytopenic
effect, even after 35 days. Measurements of Meg-CFC and
megakaryocyte ploidy during the periods of M-CSF treatment and recovery
of normal platelet levels showed no evidence of bone marrow
suppression. Platelet survival was markedly decreased after 5 days of
M-CSF (at the platelet count nadir) and after 9 days of continued M-CSF
treatment, when the platelet count had returned to normal. Platelets
from M-CSF-treated donors demonstrated normal survival when transfused
into normal recipients. We concluded that thrombocytopenia produced by
M-CSF was not due to suppression of thrombopoiesis, but to increased
activity of the monocyte/macrophage system, which caused shortened
platelet survival, and that subsequently, increased platelet production
compensated for ongoing platelet destruction and resulted in normal
platelet levels.
MACROPHAGE colony-stimulating factor
(M-CSF; CSF-1) is essential for the survival, growth, and development
of the monocyte/macrophage cell lineage.1-5 Experiments in
normal6 and M-CSF-deficient (op/op) mice7,8
suggest that M-CSF has a major regulatory role in the development and
maintenance of mononuclear phagocytes in liver, spleen, and kidney.
Most circulating M-CSF is cleared by binding to its receptor on the
macrophages of the liver and spleen, with subsequent endocytosis of the
receptor-ligand complex and intracellular degradation.9,10
M-CSF has been shown to acutely increase monocyte levels when
administered to various animals and man. The magnitude of reported
increases has been variable, but dose/response relationships have been
demonstrated.5,6,11-14 Some investigations also have
reported a return toward normal of elevated monocyte levels with
continued M-CSF administration.12,13,15,16 Bone marrow
monocyte production has been shown to be increased12;
therefore, the decrease in circulating monocytes during prolonged M-CSF
administration may be due to increased movement of monocytes into
tissues.17 M-CSF administration has been shown to cause
increases in the weights of livers and spleens, with both livers and
spleens exhibiting increased infiltrates of
macrophages.18,19 No consistent changes in the total white
blood cell (WBC), lymphocyte, or neutrophil counts are
produced by M-CSF, but occasionally increases in these cells are
reported.12,15,16 These effects may be secondary to the
induction of other cytokines produced by the responding
macrophages.20 A puzzling and major adverse effect of M-CSF
administration has been the production of thrombocytopenia in all
species studied,12,15,16,21,22 which sometimes resolves
despite continued M-CSF administration.16,22-24
Thrombocytopenia was dose-related, but was not sufficiently severe to
cause bleeding. Several reports document a temporal relationship
between the nadir of the platelet count and the maximum increase in
monocyte counts.12,13,15,20,24,25 In this investigation, we
have characterized the thrombocytopenic effect of M-CSF and have sought
to determine the mechanism of this unpredicted physiologic result and
its resolution despite continued administration of M-CSF.
General techniques.
Female Swiss Webster (SW) mice, 27 to 30 g, and female C57BL/6N (C57BL)
mice, 22 to 25 g, (Simonsen Laboratories, Gilroy, CA) were used for
these studies. Uninjected mice from the same shipments were used as
normal controls. Mice were housed in an American Association for
Accreditation of Laboratory Animal Care approved facility in filter
cages and fed standard rodent chow and tap water ad libitum. All
experimental protocols were approved by the Committee for Animal
Experimentation of the VAMC. In conducting research using animals, the
investigators adhered to the "Guide for the Care and Use of
Laboratory Animals" prepared by the Committee on Care and Use of
Laboratory Animals of the Institute of Laboratory Animal Resources,
National Research Council (National Academy Press, Washington, DC,
1996). Blood samples were obtained from the retroorbital venous plexus,
with the use of 70 µL heparinized EDTA-coated glass capillary tubes
(Drummond Scientific Co, Broomall, PA), on the days indicated,
immediately before M-CSF injection. Splenectomy was performed under
anesthesia with methoxyflurane vapor (Metofane; Pitman-Moore, Inc,
Mundelein, IL). Mice were allowed to recover from surgery for at least
1 month before experimentation. Mice were killed by cervical
dislocation.
Reagents.
Recombinant human macrophage colony-stimulating factor (M-CSF; CSF-1)
was a generous gift from the Cetus and Chiron Corporations, Emeryville,
CA. Dilutions were made in pyrogen-free 0.9% saline for injection
(Abbott Laboratories, Inc, North Chicago, IL). M-CSF was administered
by intraperitoneal (IP) injection twice daily, 8 hours apart, at the
doses indicated, in volumes of approximately 0.3 mL, beginning on day
1.
Blood cell counts.
Platelet counts, total WBC counts, and hematocrit values were
determined in whole blood diluted 1:2 (vol/vol) in isotonic saline
solution (Hematall, Fisher Scientific Co, Pittsburgh, PA) and analyzed
with an automated flow cytometric whole blood counter (Technicon H-1
System, Technicon Instruments, Tarrytown, NY), as previously
described.26
Proplatelet quantification.
Platelet morphology was quantified as previously
described.30 Briefly, blood was obtained by cardiac
puncture and anticoagulated with acid-citrate dextrose containing
prostaglandin E1, pH 6.7. Platelet-rich plasma (PRP) was
prepared by centrifugation. Platelet morphology was observed by
phase-contrast microscopy. Differential counts of platelet forms were
performed with platelets drifting slowly between the coverslip and an
ordinary glass slide using 400x magnification.
Tissue weights.
At the end of selected experiments, livers, spleens, and lungs were
removed from normal or M-CSF-treated mice and tissue weights were
recorded.
Cell culture.
Soft agar cultures of spleen and bone marrow cells from normal and
M-CSF-treated mice were prepared for quantification of
granulocyte-macrophage colony-forming cells (GM-CFC) and megakaryocyte
colony-forming cells (Meg-CFC), as previously described,31
except for the following modifications: 20% horse serum was used
instead of fetal calf serum and 0.1 mL (instead of 0.2 mL) of pokeweed
mitogen spleen cell conditioned medium was used as the source of growth
factors in each 1-mL culture. Control values were bone marrow: GM-CFC,
116 colonies/5 × 104 cells and Meg-CFC, 16 colonies/5
× 104 cells; spleen: GM-CFC, 62
colonies/106 cells, and Meg-CFC, 52
colonies/106 cells.
DNA measurements.
The ploidy distribution (DNA content) of megakaryocytes from the bone
marrow of C57BL mice was measured using two-color flow cytometry, as
previously described,32 with the following modifications: a
FACScan with Lysis II software (Becton-Dickinson, Inc, San Jose, CA)
was used for analyses. C57BL mice were used because normal SW mice
demonstrate a ploidy distribution that is too variable for precise
studies of changes in ploidy (J. Levin, unpublished observation, March
1992).
Platelet survival.
Normal SW mice, or SW mice treated with M-CSF, were used as platelet
donors and recipients for these studies. Platelet survival studies were
performed as previously described.33 Briefly, platelets
pooled from donor mice were fluorescently labeled with
5-chloromethylfluorescein diacetate (CMFDA) (Molecular Probes, Eugene,
OR) and injected into the tail veins of recipient mice. After infusion
of labeled platelets, blood samples were obtained from the retroorbital
venous plexus at 2, 4, and 6 hours and then approximately every 12
hours for the next 4 days. Blood samples were analyzed by flow
cytometry, using a FACScan, to determine the proportion of labeled
platelets present at each time point. Survival curves were constructed,
and the circulating half-life (T1/2) of the labeled
platelets was determined graphically. In addition, platelet survival
times were determined by using the multiple hit model (gamma
function)34,35 and the best fit estimate, derived from the
use of both linear and exponential sum of squares
calculations.33
Carbon clearance.
The rate of disappearance of carbon particles from the circulating
blood of normal or M-CSF-treated mice was measured as previously
described.36 Briefly, a solution of India Ink (Difco
Laboratories, Detroit, MI) was injected intravenously into either
normal or M-CSF-treated mice. Blood samples were obtained at various
times from 1 to 11 minutes after injection. Blood was lysed, and
duplicate aliquots of each sample were read spectrophotometrically to
determine the absorbance at 620 nm. The background values, obtained
from lysed blood from mice not injected with carbon particles, were
subtracted. Resultant values were used to determine the disappearance
rate (T1/2) of carbon particles from the blood.
Levels of M-CSF and anti-M-SF antibodies in serum.
Serum samples were obtained 4 and 8 hours after administration of 4
mg/kg/d M-CSF on days 1, 3, and 5 for determination of circulating
M-CSF levels. Samples were stored at Statistical analysis.
Statistical analyses were performed with a two-tailed Student's
t-test, using StatView (Abacus Concepts, Berkeley, CA).
Effect of M-CSF on platelet levels.
The effect of different doses of M-CSF on the platelet counts of normal
mice was examined. M-CSF was administered to SW mice for 5 days, in 2
daily IP injections, at doses of 2, 4, or 8 mg/kg/d. The platelet
counts gradually decreased in a dose-dependent manner during the period
of administration, reached a nadir on days 4 to 5, and immediately
began to increase to above normal levels on discontinuation of
treatment (Fig 1A). Blood sampling alone
had no effect on the platelet count (data not shown).
Effect of M-CSF on circulating blood cell levels.
The effect of M-CSF, 4 mg/kg/d, on the blood cell counts of normal mice
was documented. Blood samples were obtained on days 3 and 5 of M-CSF
treatment, and days 8 and 10, after completion of the 5 days of M-CSF
treatment. Total nucleated WBC counts, platelet counts, and hematocrit
values were obtained. Differential cell counts were performed on
cytocentrifuged buffy coat preparations in which monocytes had been
specifically stained (see Materials and Methods) (Fig
3), and neutrophils and lymphocytes were
identified by standard morphologic characteristics. Total monocytes
were significantly increased over control levels of 0.28 ± 0.4
× 103/µL (mean ± 1 standard error
[SE]) on days 3 (0.85 ± 0.17 ×
103/µL) (P < .05) and 5 (0.99 ± 0.25
× 103/µL) (P < .05) of M-CSF
treatment (Fig 4). The platelet count was
significantly and maximally decreased from normal levels at the time of
maximum absolute monocytosis. The total WBC count was significantly
increased only on day 8, from the control level of 6.0 ± 0.3
× 103/µL to 8.9 ± 0.8 ×
103/µL (P < .05). The hematocrit fell from an
initial value of 52.0% ± 0.7% to a nadir of 44.6% ± 1.3% on
day 5 of M-CSF treatment, and then gradually returned to normal.
Effect of splenectomy on M-CSF-induced thrombocytopenia.
The possible role of splenic platelet sequestration in the production
of thrombocytopenia after M-CSF administration was examined.
Splenectomized animals were given M-CSF, 2 mg/kg/d, and the platelet
counts were compared with those of intact animals treated with the same
dosage. Platelet counts fell to equivalent levels in intact and
splenectomized SW mice during M-CSF treatment, and splenectomy did not
affect either the degree of the thrombocytopenia or subsequent rebound
thrombocytosis produced (Fig 5).
Effect of M-CSF on colony-forming cells.
Soft agar cultures were performed to determine the total number of
GM-CFC and Meg-CFC in spleen and bone marrow. M-CSF, 2 mg/kg/d, was
administered to mice for up to 5 days, and total colony numbers were
determined on days 2, 4, 5, 6, and 8. Both GM and Meg colony numbers
remained normal on day 2 and then were increased twofold to sixfold
over controls in the spleens of M-CSF-treated mice on days 4 to 8. The
maximum increase in the spleen occurred on days 5 and 6. However, there
were no differences between the total numbers of detectable GM-CFC or
Meg-CFC present in the bone marrows of M-CSF-treated and normal mice
(data not shown).
Effect of M-CSF on DNA levels in megakaryocytes.
The effect of M-CSF on the ploidy distribution of megakaryocytes in
C57BL mice was analyzed. M-CSF, 2 mg/kg/d, was administered on days 1
to 5. DNA content (ploidy) of bone marrow megakaryocytes was analyzed
on days 3 to 7 (Fig 6). On days 4 to 7, the
proportion of 32N, 64N, and 128N megakaryocytes was significantly
increased over control levels (Fig 6C through F). However, although the
proportion of 16N megakaryocytes decreased on days 6 and 7 as the
higher ploidy megakaryocytes were increasing, 16N megakaryocytes
remained the modal class. A higher dose of M-CSF, 8 mg/kg/d, which
produced more severe thrombocytopenia, also significantly increased the
proportion of 32N, 64N, and 128N classes on days 6 and 7 (Fig 6G
through H), and in addition, 32N became the modal class on day 7.
Effect of M-CSF on platelet survival.
To more thoroughly investigate the possible cause of thrombocytopenia
and the role of the spleen, platelet survival in M-CSF-treated
eusplenic and splenectomized mice was determined. M-CSF, 4 mg/kg/d, was
administered to groups of eusplenic and asplenic SW mice starting on
day 1. On day 4, pooled platelets harvested from normal mice and
labeled with CMFDA were injected intravenously into the treated mice
and a control group. M-CSF injections continued through day 5, and
platelet survival was measured for 93 hours after injection of labeled
platelets (Fig 7). The circulating
half-life (T1/2) of the labeled platelets in the control
group was 32.9 ± 2.3 hours, and platelet survival, as measured by
the multiple hit model (gamma function) was 2.58 ± 0.18
days. The T1/2 of the labeled platelets was markedly
reduced to 19.0 ± 0.7 hours in the eusplenic M-CSF-treated mice,
and to 16.3 ± 1.7 hours in the asplenic mice (for both,
P < .001 v control). Platelet survival was
significantly shorter in M-CSF-treated recipient animals (1.19 ±
0.07 days in eusplenics and 1.06 ± 0.15 days in asplenics [for
both, P < .001 v control]). There was no difference
between the circulating half-life (T1/2) or platelet
survival in eusplenic and asplenic animals. Platelet survival also was
examined in animals in which M-CSF, 4 mg/kg/d, was administered for 8
days before the injection of labeled platelets and was continued
throughout the experiment. The T1/2 of the labeled
platelets in these animals was 26.2 ± 3.1 hours, and the platelet
survival was 2.07 ± 0.43 days (P < .01 v control)
(data not shown). Similar results were obtained for all these
experimental groups when platelet survival estimates also were
calculated using the best fit method (data not shown).
Effect of M-CSF on the monocyte/macrophage (reticuloendothelial)
system.
To evaluate the effect of M-CSF on the monocyte/macrophage system,
carbon clearance experiments were performed in mice that had been
treated with M-CSF, 4 mg/kg/d, for various lengths of time. Absorbance
(at 620 nm) due to the presence of carbon particles was monitored
beginning at 1 minute after bolus injection to ensure homogeneous
intravascular distribution of particles. Clearance of intravenously
injected India Ink particles was significantly faster in mice that had
been treated with M-CSF for 3, 5, or 9 days (Fig
9). The T1/2 of the carbon
particles in mice treated for 3 days was 3.7 ± 0.4 minutes; for 5
days, 2.8 ± 0.2 minutes; and for 9 days, 3.9 ± 0.5 minutes,
compared with the control value of 12.0 ± 0.7 minutes (for all,
P < .0001). Furthermore, the measured 1-minute absorbance
values (A620) were 1.091 for the control, 0.717 for the 3-day group,
0.566 for the 5-day group, and 0.637 for the day 9 group, indicating
that there was greater clearance of carbon particles during the first
minute in M-CSF-treated mice than in controls. Carbon clearance
remained faster than normal in mice treated for 9 days with M-CSF,
indicating that the monocyte/macrophage system remained hyperactive
despite recovery of the platelet count.
Effect of M-CSF on the liver, spleen and lung weights.
In selected experiments, livers, spleens, and lungs were removed from
M-CSF-treated animals after sacrifice. After administration of M-CSF,
4 mg/kg/d for 5 days, the livers and spleens of treated mice were
significantly larger than those of the control animals. On day 5, liver
weights were increased to 2.0 g (n = 14), from the control value of 1.3
g (n = 19) (P < .001), but by day 9, they were 1.4 g, almost
normal. Spleen weights were increased to 250 mg on day 5 (n = 14), in
contrast to the control value of 136 mg (n = 19) (P < .001)
and remained increased (208 mg) on day 9 (n = 9). Total lung weights
were not significantly increased on day 5 or day 9 from the control
value of 157 mg (n = 8). After 9 days of administration of the same
dose of M-CSF, liver weights were comparably increased to 2.0 g (n =
4), and spleen weights were increased further to 289 mg (n = 4).
Effect of M-CSF on proplatelet formation.
Proplatelet formation was quantified as a potential indicator of
stimulation of platelet production. M-CSF, 4 mg/kg/d, was administered
for up to 5 days, and platelet differentials were performed on days 3,
5, and 9. At these times, when platelet levels were either falling (day
3), at their nadir (day 5), or increasing (day 9), the proportion of
proplatelets was not increased (Table 1).
However, the absolute numbers of proplatelets circulating on day 5 were
significantly decreased from control levels, and conversely, were
significantly increased on day 9 (Table 1).
Our studies have confirmed previous reports that M-CSF can produce
thrombocytopenia.11,12,15,16,21,22 In addition, we have
attempted to define the mechanisms of the production of
thrombocytopenia by M-CSF and of the recovery of platelet levels during
its continued administration. Treatment with M-CSF for 5 days produced
dose-dependent thrombocytopenia, with rapid recovery of normal platelet
levels and subsequent development of rebound thrombocytosis occurring
after discontinuation of treatment. However, in experiments in which
M-CSF was administered over a longer period, platelet levels
surprisingly began to recover after 5 days, despite continued
administration of M-CSF, strongly suggesting that thrombocytopenia was
not the result of suppression of platelet production. Additional
evidence for this hypothesis was that the ploidy distribution of
megakaryocytes in the bone marrow remained essentially normal during
the period of falling platelet levels, which reached their nadir on
days 4 to 5. In contrast, in a model of bone marrow damage, produced by
administration of 5-fluorouracil (5-FU) to mice, the proportion of
higher ploidy megakaryocytes decreased initially, with 8N becoming the
modal class on day 4.40 After M-CSF, we did not observe a
decrease in the proportion of 16N and 32N megakaryocytes, but rather
observed a slight right shift in ploidy. No changes were observed in
the total GM-CFC and Meg-CFC in the bone marrow following M-CSF, in
contrast to the marked increases observed during recovery from bone
marrow damage produced by 5-FU.41 The rapidity of the
recovery to normal or above normal platelet levels after termination of
M-CSF treatment also argues against bone marrow suppression.
Submitted April 7, 1997;
accepted August 28, 1997.
The authors thank Dr Jolanda Schreuers (formerly of Chiron Corp) for
helpful discussions and assistance in making these studies possible,
and Dr E. Richard Stanley, Albert Einstein College of Medicine, whose
laboratory determined the M-CSF levels and anti-M-CSF antibody titers.
1.
Ralph P,
Sampson-Johannes A:
Macrophage growth and stimulating factor, M-CSF.
Prog Clin Biol Res
338:43,
1990[Medline]
[Order article via Infotrieve]
2.
Roth P,
Stanley ER:
The biology of CSF-1 and its receptor.
Curr Top Microbiol Immunol
181:141,
1992[Medline]
[Order article via Infotrieve]
3.
Stanley ER,
Guilbert LJ,
Tushinski RJ,
Bartelmez SH:
CSF-1-A mononuclear phagocyte lineage-specific hemopoietic growth factor.
J Cell Biochem
21:151,
1983[Medline]
[Order article via Infotrieve]
4.
Metcalf D:
Studies on colony formation in vitro by mouse bone marrow cells. II. Action of colony stimulating factor.
J Cell Physiol
76:89,
1970[Medline]
[Order article via Infotrieve]
5. Nemunaitis J, Singer JW: Macrophage colony-stimulating factor:
Biology and clinical applications, in Armitage JO and Antman KH (eds):
High-dose Cancer Therapy. Pharmacology, Hematopoietins,
Stem Cells. Baltimore, MD, Williams & Wilkins, 1992, p 344
6.
Hume DA,
Pavli P,
Donahue RE,
Fidler IJ:
The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte system in vivo.
J Immunol
141:3405,
1988[Abstract]
7.
Cecchini MG,
Dominguez MG,
Mocci S,
Wetterwald A,
Felix R,
Fleisch H,
Chisholm O,
Hofstetter W,
Pollard JW,
Stanley ER:
Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse.
Development
120:1357,
1994[Abstract]
8.
Wiktor-Jedrzejczak W,
Urbanowska E,
Aukerman SL,
Pollard JW,
Stanley ER,
Ralph P,
Ansari AA,
Sell KW,
Szperl M:
Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor.
Exp Hematol
19:1049,
1991[Medline]
[Order article via Infotrieve]
9. Stanley ER: Colony stimulating factor-1 (macrophage colony
stimulating factor), in Thomson AW (ed): The Cytokine Handbook. San
Diego, CA, Academic, 1994, p 387
10.
Bartocci A,
Mastrogiannis DS,
Migliorati G,
Stockert RJ,
Wolkoff AW,
Stanley ER:
Macrophages specifically regulate the concentration of their own growth factor in the circulation.
Proc Natl Acad Sci USA
84:6179,
1987
11.
Garnick MB,
Stoudemire JB:
Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF).
Int J Cell Cloning
8:356,
1990
12.
Munn DH,
Garnick MB,
Cheung N-KV:
Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates.
Blood
75:2042,
1990
13.
Cole DJ,
Sanda MG,
Yang JC,
Schwartzentruber DJ,
Weber J,
Ettinghausen SE,
Pockaj BA,
Kim HI,
Levin RD,
Pogrebniak HW,
Balkissoon J,
Fenton RM,
DeBarge LR,
Kaye J,
Rosenberg SA,
Parkinson DR:
Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
J Natl Cancer Inst
86:39,
1994
14.
Redman BG,
Flaherty L,
Chou TH,
Kraut M,
Martino S,
Simon M,
Valdivieso M,
Groves E:
Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.
J Immunother
12:50,
1992
15.
Garnick MB,
O'Reilly RJ:
Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6.
Hematol Oncol Clin North Am
3:495,
1989[Medline]
[Order article via Infotrieve]
16.
Vitt CR,
Fidler JM,
Ando D,
Zimmerman RJ,
Aukerman SL:
Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat.
J Infect Dis
169:369,
1994[Medline]
[Order article via Infotrieve]
17.
Munn DH,
Cheung N-KV:
Preclinical and clinical studies of macrophage colony-stimulating factor.
Semin Oncol
19:395,
1992[Medline]
[Order article via Infotrieve]
18.
Bock SN,
Cameron RB,
Kragel P,
Mulé JJ,
Rosenberg SA:
Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
Cancer Res
51:2649,
1991
19.
Stoudemire JB,
Garnick MB:
Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels.
Blood
77:750,
1991
20. Sherr CJ, Stanley ER: Colony-stimulating factor 1 (macrophage
colony-stimulating-factor), in Sporn MB and Roberts AB (eds): Handbook
of Experimental Pharmacology, vol. 95/I, Peptide Growth Factors and
Their Receptors. Berlin, Germany, Springer-Verlag, 1990, p 667
21. Johnson CW, Nachtman JP, Cimprich RE, Moon H-L, Mills SE,
Beckendorf J, Levine BS, Long RC, Fuller GB, Losos G, Provencher A,
Stoll RE: Clinical and histopathological effects of M-CSF in laboratory
animals, in Richter GW, Solez K (eds): International Review of
Experimental Pathology, vol 34. San Diego, CA, Academic, 1993, p 189
22.
Zamkoff KW,
Hudson J,
Groves ES,
Childs A,
Konrad M,
Rudolph AR:
A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy.
J Immunother
11:103,
1992
23.
Schaub RG,
Bree MP,
Hayes LL,
Rudd MA,
Rabbani L,
Loscalzo J,
Clinton SK:
Recombinant human macrophage colony-stimulating factor reduces plasma cholesterol and carrageenan granuloma foam cell formation in Watanabe heritable hyperlipidemic rabbits.
Arterioscler Thromb
14:70,
1994
24.
Weiner LM,
Li W,
Holmes M,
Catalano RB,
Dovnarsky M,
Padavic K,
Alpaugh RK:
Phase I trial of recombinant macrophage colony-stimulating factor and recombinant
25.
Jakubowski AA,
Bajoran DF,
Templeton MA,
Chapman PB,
Cody BV,
Thaler H,
Tao Y,
Filippa DA,
Williams L,
Sherman ML,
Garnick MB,
Houghton AN:
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.
Clin Cancer Res
2:295,
1996
26.
Davis E,
Corash L,
Baker G,
Mok Y,
Hill RJ,
Levin J:
Splenic thrombopoiesis after bone marrow ablation with radiostrontium: A murine model.
J Lab Clin Med
116:879,
1990[Medline]
[Order article via Infotrieve]
27.
Guilbert LJ,
Stanley ER:
Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells.
J Cell Biol
85:153,
1980
28.
DeLamarter JF,
Hession C,
Semon D,
Gough NM,
Rothenbuhler R,
Mermod J-J:
Nucleotide sequence of a cDNA encoding murine CSF-1 (macrophage-CSF).
Nucleic Acids Res
15:2389,
1987
29.
Flanagan JG,
Leder P:
The kit ligand: A cell surface molecule altered in steel mutant fibroblasts.
Cell
63:185,
1990[Medline]
[Order article via Infotrieve]
30.
Tong M,
Seth P,
Penington DG:
Proplatelets and stress platelets.
Blood
69:522,
1987
31.
Levin J,
Levin FC,
Metcalf D:
The effects of acute thrombocytopenia on megakaryocyte-CFC and granulocyte-macrophage-CFC in mice: Studies of bone marrow and spleen.
Blood
56:274,
1980
32.
Corash L,
Levin J,
Mok Y,
Baker G,
McDowell J:
Measurement of megakaryocyte frequency and ploidy distribution in unfractionated murine bone marrow.
Exp Hematol
17:278,
1989[Medline]
[Order article via Infotrieve]
33.
Baker GR,
Sullam PM,
Levin J:
A simple, fluorescent method to internally label platelets suitable for physiological measurements.
Am J He |
Abstract
Introduction
Abstract
70°C until assayed.
Radioimmunoassays were performed in duplicate in a two-step procedure
as previously described by Stanley
, 2 mg/kg/d v 4 mg/kg/d; 
,
2 mg/kg/d v 8 mg/kg/d; #, 4 mg/kg/d v 8 mg/kg/d). (B)
The effect of administration for 11 days of different doses of M-CSF on
the platelet counts of SW mice. M-CSF was administered to SW mice at
the indicated dosages, given in two daily IP injections, 8 hours apart,
for 11 days. Platelet counts were obtained immediately before the
morning M-CSF injection. The mean platelet count ± 1 SE is shown. The
number of determinations ranged from 5 to 21 at each time point (mean,
11). The symbols indicate significant differences between the values
(P < .05) (
) was 32.9 hours (n = 5). The T1/2 in the eusplenic
M-CSF treated animals (
) (19.0 hours; n = 7) and in the asplenic
M-CSF-treated animals (
) (16.3 hours; n = 7) were both
significantly shorter than that of the controls (P < .001).
The T1/2 values for platelet survival in the 2 groups of
M-CSF-treated animals were not significantly different from each
other. Serial platelet counts for each group were obtained and are
shown with the corresponding open symbols in the inset graph.
-interferon: Toxicity, monocytosis, and clinical effects.
Cancer Res
54:4084,
1994